FUNDAMENTALS · Fundamentals · US Healthcare

SeaStar Medical Holding (ICU) Fundamentals 2026 — Revenue Analysis | SniperIQ

SeaStar Medical Holding (ICU) is a US-listed Healthcare company in Biotechnology with a market capitalization of

1M, trading at
.92 on the NASDAQ. This SniperIQ fundamentals page covers SeaStar Medical Holding's valuation, profitability (net margin -828.6%), revenue (
M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
1M
Net Margin-828.6%
Revenue (FY25)
M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is SeaStar Medical Holding's market cap?

SeaStar Medical Holding (ICU) has a market capitalization of approximately

1M, trading at
.92 on the NASDAQ. Market cap moves with the live share price.

What is SeaStar Medical Holding's P/E ratio?

SeaStar Medical Holding's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 21.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is SeaStar Medical Holding?

SeaStar Medical Holding runs a net profit margin of -828.6%, a gross margin of 93.1%, and an operating margin of -832.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does SeaStar Medical Holding generate?

SeaStar Medical Holding reported revenue of

M for fiscal year 2025, with net income of -
2M and earnings per share (EPS) of -5.86. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does SeaStar Medical Holding pay a dividend?

SeaStar Medical Holding does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is SeaStar Medical Holding financially healthy?

SeaStar Medical Holding carries a debt-to-equity ratio of 0.05x and a current ratio of 2.73x, with a market beta of -1.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is SeaStar Medical Holding a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SeaStar Medical Holding (ICU) the key facts are: market cap

1M, revenue
M, 52-week range 2.07-12.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track SeaStar Medical Holding's full fundamentals live

Get SeaStar Medical Holding's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Akari Therapeutics (AKTX) fundamentals · Kiora Pharmaceuticals (KPRX) fundamentals · CytoMed Therapeutics (GDTC) fundamentals · Satellos Bioscience (MSLE) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons